in the absence of a submission from the holder of the marketing authorisation:
elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide (Genvoya®) is not recommended for use within NHSScotland.
Indication under review: treatment of human immunodeficiency virus-1 (HIV-1) infection without any known mutations associated with resistance to the integrase inhibitor class, emtricitabine or tenofovir in paediatric patients aged from 2 years and with body weight at least 14 kg to less than 25 kg.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result, we cannot recommend its use within NHSScotland.
Download detailed advice242KB (PDF)
Medicine details
- Medicine name:
- elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide (Genvoya)
- SMC ID:
- SMC2809
- Indication:
Treatment of human immunodeficiency virus-1 (HIV-1) infection without any known mutations associated with resistance to the integrase inhibitor class, emtricitabine or tenofovir in paediatric patients aged from 2 years and with body weight at least 14 kg to less than 25 kg.
- Pharmaceutical company
- Gilead Sciences Ltd
- BNF chapter
- Infections
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 12 May 2025